100 years ago, scientists thought we'd be eating food made from air
In August 1925, Popular Science contributing writer Norman C. McCloud described how Daniel Berthelot—a decorated chemist and physicist from France—was conducting revolutionary 'factory-made vegetable' experiments in his Garden of Wonders. Berthelot, son of Marcellin Berthelot, a renowned 19th century chemist and French diplomat, was using the garden to expand upon his father's groundbreaking work. Starting in 1851, the elder Berthelot began creating synthetic organic compounds, such as fats and sugars (he coined the name 'triglyceride'), from inorganic compounds like hydrogen, carbon, oxygen, and nitrogen. It was a revolutionary first step toward artificial food.
'[The younger] Berthelot already has produced foodstuffs artificially by subjecting various gases to the influence of ultra-violet light,' wrote McCloud. 'These experiments,' he added, quoting Berthelot, 'show that by means of light, vegetable foods can be manufactured from air gases.' But Berthelot's experiment didn't exactly catch on. A century later, most food is still grown the traditional way—by plants—but the idea of manufacturing food in controlled, factory environments has been gaining ground. In fact, Berthelot's revolutionary idea may finally be bearing fruit—just not in the way he imagined.
A revolution in food chemistry
Berthelot never fully accomplished his goal of trying to artificially reproduce what plants do naturally. Nonetheless, his experiments, as sensational as they might seem today, would have been considered quite plausible in 1925. That's because his father's discoveries had unleashed a revolution in chemistry and a tidal wave of optimism about the future of food. By the 1930s, chemists had begun synthesizing everything from basic nutrients, like vitamins, to medicines, like aspirin (acetylsalicylic acid), to food additives, such as artificial thickeners, emulsifiers, colors, and flavors.
In an interview for McClure's magazine in 1894 dubbed 'Foods in the Year 2000,' Berthelot's father boldly predicted that all foods would be artificial by the year 2000. 'The epicure of the future is to dine upon artificial meat, artificial flour, and artificial vegetables,' wrote Henry Dam for McClure's, articulating Marcellin Berthelot's vision. 'Wheat fields and corn fields are to disappear from the face of the earth. Herds of cattle, flocks of sheep, and droves of swine will cease to be bred because beef and mutton and pork will be manufactured direct[ly] from their elements.'
Welcome to the Garden of Wonders
Such was the vision that the younger Berthelot was pursuing in his Garden of Wonders. His goal, he told McCloud, was to produce 'sugar and starch from the elements without the intervention of living organisms.' To achieve this, Berthelot envisioned a factory with 'glass tanks of great capacity.' Gases would be pumped into the tanks, and 'suspended from the ceiling [would] be lamps producing the rays of ultra-violet light.' Berthelot imagined that when the chemical elements combined 'through the glass walls of the tank we shall see something in the nature of a gentle snowfall that will accumulate on the floor of the tanks…our finished product—vegetable starches and vegetable sugars created in a faithful reproduction of the works of nature.'
By 1925, he had succeeded in using light and gas (carbon, hydrogen, oxygen, and nitrogen) to create the basic compound formamide, which is used to produce sulfa drugs (a kind of synthetic antibiotic) and other medicines as well as industrial products. But his progress toward reproducing photosynthesis ended there. Berthelot died just two years after McCloud's story ran in Popular Science, in 1927, without ever realizing his dream.
Despite the bold predictions of the time, producing food from only air and light was wildly aspirational in 1925, if for no other reason than photosynthesis was poorly understood. The term had only been coined a few decades earlier when Charles Barnes, an influential American botanist, lobbied for a more precise description of a plant's internal mechanisms than the generic 'assimilation' then in favor. Chlorophyll had been discovered in the prior century, but what happened at a cellular level in plants remained largely theoretical until the 1950s. Although Berthelot may have been onto something with his experiments, adding to the momentum that became the artificial food industry, he was a long way from replicating what comes naturally to plants. We still are, but recent discoveries may have enabled a workaround—depending on your definition of 'food.'
A modern answer to Berthelot's innovative garden
From vertical indoor farms to hydroponics to genetically modified crops, since the 1960s commercial agriculture has been focused on coaxing more yield from fewer resources, including land, water, and nutrients. The drive began when Nobel Peace Prize winner Norman Borlaug, an American biologist, helped spark the Green Revolution by selectively breeding a grain-packed, dwarf variety of wheat. The theoretical limit of that revolutionary goal would liberate food production from traditional agriculture altogether, eliminating all resources except air and light—Berthelot's original vision.
In the last century, we've inched toward creating food from nothing, making progress by teasing apart the incredibly complex biochemical pathways associated with plant physiology. But if we've learned anything since Berthelot's experiments, it's that photosynthesis—what plants are naturally programmed to do—can't be easily replicated industrially. But that hasn't stopped a handful of companies from trying.
In April 2024, Solar Foods opened a factory in Vantaa, Finland—a sleek facility where workers monitor large tanks filled with atmospheric gases. Inside the tanks, water transforms into a protein-rich slurry. Dehydrated, the slurry becomes a golden powder packed with protein and other nutrients, ready to be turned into pasta, ice cream, and protein bars. The powdery substance, Solein, resembles Berthelot's vision, as does the factory, which uses atmospheric gases to enable 'food production anywhere in the world,' according to a 2025 company press release, 'as production is not dependent on weather, climate conditions, or land use.' But the similarities with Berthelot's vision end there. Solar Foods may not require land or plants to produce food, but their technology derives from a living organism. Using a form of fermentation, it relies on a microbe to digest air and water to produce protein.
Related Archival Stories
100 years ago, scientists predicted we'd live to 1,000 years old
100 years ago, the battle for television raged
A century ago, suspended monorails were serious mass-transit contenders
100 years of deep-sea filmmaking and ocean exploration
100 years of aliens: From Mars beavers to little gray men
The U.S.-based company Kiverdi uses a similar microbial fermentation process, first devised by NASA as far back as the 1960s for deep space travel, to convert carbon dioxide into protein. Austria-based Arkeon Technologies has developed its own microbial fermentation process to also produce food from carbon dioxide without the need for land or other nutrients. Microbial fermentation may represent a promising new chapter in synthetic foods, but don't expect tomatoes or corn to materialize from thin air anytime soon—it's not artificial photosynthesis.
While Berthelot's understanding of photosynthesis was primitive a century ago, he was ahead of his time in many ways, and his vision was remarkably prescient. Although we still haven't figured out how to replicate photosynthesis chemically—literally growing fruits and vegetables as plants do from air and light—it's worth acknowledging the strides we've made in just the last decade: Companies like Arkeon Technologies and Kiverdi may help remove excess carbon dioxide from the atmosphere while offering solutions to future food shortages. Or they may not. Only the next century will tell.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
The world's first jump jet: How we got the legendary Harrier II
The Hawker Siddeley Kestrel was the aviation world's first jump jet, a Vertical/Short Take-Off and Landing (or V/STOL) aircraft, a milestone in aviation history. Originally known as the P.1127, it was later renamed the Hawker Siddeley Kestrel. Its evolution led to the British Aerospace Harrier and ultimately the McDonnell Douglas AV-8 Harrier II. No Runways After the Korean War, interest in V/STOL aircraft was high. Military planners and aircraft manufacturers believed the concept would eliminate the need for runways, which were vulnerable to air-launched runway denial munitions, as well as cannon and mortar fire. Designers began to research ways for military aircraft to take off vertically from small patches of open space. The Pegasus Engine The Pegasus vectored-thrust engine is the heart of the Kestrel/Harrier aircraft. The Pegasus moniker came from Bristol's tradition of naming their engines after classic mythology figures. Its original design and theory behind the vectored-thrust engine came from Michel Wibault, a French aviation designer. His design called for four harnessed rotatable jets, two of which were positioned on either side of the compressor for vertical lift, along with a main jet which was directed using a fixed central tailpipe. Development of the engine and aircraft began in 1957. Sir Stanley Hooker of the Bristol Aero Engine Company, along with Sir Sydney Camm and Ralph Hooper of Hawker Aircraft, started exploring ways to increase power while reducing the size and weight of the engine. By 1959, a working engine was ready for testing, but the thrust of the original engine was only 11,000 pounds instead of the promised 13,500 pounds. First Flight In October 1960, initial flights of the prototype were conducted with the aircraft tethered to the ground. This testing allowed the pilots to familiarize themselves with the hovering controls. In November 1960, the first untethered flights began, and by September 1961, the transition from vertical to horizontal flight was achieved. Summer In Paris In June 1963, the Hawker Siddeley P.1127 made its debut at the Paris Air Show. While it performed well for most of the demonstration, the landing didn't go well, as viewers watched the aircraft perform a 360-degree turn and then lose power, resulting in a hard landing that destroyed the undercarriage. Dreihundert Zwei! In 1965, a Tripartite Evaluation Squadron (TES) was formed at West Raynham, Norfolk, England, comprising top pilots from the United Kingdom, the Federal Republic of Germany, and the United States of America. This team would conduct trials of the Kestrel FGA.1 for their respective air forces. West Germany sent Luftwaffe Col. Gerhard Barkhorn as their representative. Barkhorn, who gained notoriety for destroying a total of 301 aircraft during World War II, was testing one of the Kestrels on Oct. 13, 1965. As he was hovering, about to land, he cut the throttle approximately one meter above the ground. The Kestrel dropped like a stone, destroying the landing gear. Barkhorn climbed out of the cockpit and, while examining the damage, exclaimed, 'Driehundert Zwei!' German for '302.' Coming to America Following a meeting and a rumored unauthorized test flight between two Marine Corps pilots and representatives from Hawker Siddeley at the 1968 Farnborough Air Show, the Marine Corps decided it wanted the Harrier for close air support and carrier operations. As Hawker Siddeley produced the Harrier, an arrangement had to be made with the U.S. defense contractor McDonnell-Douglas to produce this foreign-made aircraft. Between 1971 and 1976, the Marine Corps procured 102 AV-8A Harriers and 8 TAV-8A two-seat training aircraft. Off To War In 1980, British Aerospace delivered the first of 57 FRS.1 Sea Harriers (also known as the 'Shar') to the Royal Navy. They proved their worth just two years later in 1982, when the United Kingdom went to war in the Falklands. Operating from carriers in the war zone off the coast of Argentina, they provided air defense for the British Task Force. They shot down 20 Argentinian aircraft with the loss of just two Harriers. AV-8B Harrier II In December 1983, the Marine Corps received its first upgraded Harrier II. This version was an extensive redesign of the AV-8A Harrier. The Harrier II was upgraded with a larger composite wing, an additional hardpoint on each side, an elevated cockpit, and an upgraded version of the Pegasus engine, producing 23,500 pounds of thrust. The Legacy The Harrier was an outstanding weapons system that served for decades through war and peace, but Father Time comes for everything sooner or later. By 2027, the last of the Marine Corps Harriers will be retired, and the squadrons will transition to the new kid in town: the Lockheed F-35B Lightning II. Aviation Aviation The world's first jump jet: How we got the legendary Harrier II By Friedrich Seiltgen Fixed Wing Why Saddam Hussein buried Iraq's air force in the desert Why Saddam Hussein buried Iraq's air force in the desert By Blake Stilwell Aviation The Navy is spending $1.1 billion on the most successful air-to-air missile in the world The Navy is spending $1.1 billion on the most successful air-to-air missile in the world By Miguel Ortiz Aviation If the F-47 is named after Trump, here are the namesakes of America's other fighter jets If the F-47 is named after Trump, here are the namesakes of America's other fighter jets By Logan Nye Fixed Wing How fighter jets can 'headbutt' enemy planes How fighter jets can 'headbutt' enemy planes By Logan Nye Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Elsevier introduces Reaxys AI Search, enabling faster and more accessible chemistry research through natural language discovery
With Reaxys AI Search, chemists and R&D teams can explore over 121 million chemistry documents, patents and peer-reviewed journal articles, unlocking more relevant insights faster and accelerating discovery Reaxys AI Search avoids the need to construct complex keyword searches, making it invaluable for interdisciplinary research such as materials science, chemical engineering, and polymer science LONDON, July 31, 2025 /PRNewswire/ -- Elsevier, a global leader in advanced information and decision support in science and healthcare, introduces Reaxys AI Search, an innovative addition to the Reaxys platform that leverages AI-driven natural language processing to transform chemistry research. Reaxys is the first chemistry database to introduce natural language document search to enhance the discoverability of relevant documents as researchers navigate vast amounts of complex chemical research information. Reaxys AI Search is especially impactful in interdisciplinary R&D fields such as materials science, chemical engineering, and polymer science, as it eliminates the need to construct complex keyword searches. Instead, Reaxys AI Search interprets user intent, handles spelling variations, abbreviations and synonyms, and returns the most relevant documents for each query. This means chemists, chemical and material engineers, polymer scientists, pharmaceutical and biotech professionals, academic researchers and other users spend less time searching for relevant insights and more time focusing on discovery and innovation. Built on Reaxys' trusted and comprehensive database, Reaxys AI Search taps into over 121 million documents, including patents and peer-reviewed journal articles, to consistently deliver high levels of precision and recall in the answers it provides. Reaxys AI Search, developed through testing with hundreds of chemists, is an important step in the AI transformation of Reaxys, following the release of the award-winning Reaxys Predictive Retrosynthesis. Future releases will see further refinements of the AI search options, along with advanced summarization capabilities. Mirit Eldor, Managing Director, Life Sciences, Elsevier, said: "Reaxys AI Search marks a major step in making chemistry data more accessible and actionable. By enabling natural language queries, we aim to lower barriers for researchers across disciplines and experience levels to find the information they need faster and with greater confidence. Launching this early version allows us to deliver immediate value to researchers while gathering feedback to continually refine the solution as part of our commitment to innovation that helps advance human progress." The early release version of Reaxys AI Search is available now to all Reaxys users. Users can access this feature within the existing platform alongside the existing structure and keyword search options, providing immediate hands-on experience. Elsevier remains committed to working closely with the scientific community to refine and expand this technology, ensuring it meets the evolving needs of chemistry research. Reaxys AI Search was developed in accordance with Elsevier's Responsible AI Principles and Privacy Principles, prioritizing data privacy, security, and transparency. All user interactions are private, with no data used to train external models, and results are generated from trusted, curated content. To learn more or request access to the Reaxys AI Search, visit About Elsevier Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit and follow us on social media @elsevierconnect. Logo: View original content to download multimedia: SOURCE Elsevier Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
AB Science announces the successful completion of a 2.55 million euros private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 2.55 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 2,276,787 new ordinary shares of the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 3.34% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 3.23% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on August 1st, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 24, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.12 (including share issue premium), representing a facial discount of 24.68% (i.e. EUR 0.3669) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. August 1st and July 31 and 30, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 17.87% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.71 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 2,276,787 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.89 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of August 1st, 2025, is equal to EUR 0.3877 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to August 11, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 704,695.95 (or EUR 727,463.82 in the event of exercise of all BSAs). It will be comprised of 63,706,916 ordinary shares (or of 65,983,703 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. To the Company's knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company's share capital is as follows: Shareholders Before the capital increase After the capital increase (before exercising the warrants) After the capital increase and exercise of the warrant Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) A. Moussy 7 345 396 10,77% 17,57% 7 345 396 10,42% 17,12% 7 345 396 10,10% 16,69% AMY SAS (3) 12 273 000 18,00% 14,20% 12 273 000 17,42% 13,84% 12 273 000 16,87% 13,49% Subtotal concert A. Moussy 19 618 396 28,77% 31,77% 19 618 396 27,84% 30,96% 19 618 396 26,97% 30,18% Other investors members of the concert 2 625 327 3,85% 5,97% 2 625 327 3,73% 5,82% 2 625 327 3,61% 5,67% Actions in the pact 1 123 902 1,65% 4,24% 1 123 902 1,59% 4,13% 1 123 902 1,54% 4,02% Actions outside the pact 1 501 425 2,20% 1,74% 1 501 425 2,13% 1,69% 1 501 425 2,06% 1,65% Total concert 22 243 723 32,62% 37,74% 22 243 723 31,56% 36,78% 22 243 723 30,58% 35,86% Other investors above 5% 6 888 610 10,10% 9,33% 6 888 610 9,78% 9,09% 6 888 610 9,47% 8,86% Other investors 39 060 475 57,28% 52,93% 41 337 262 58,66% 54,14% 43 614 049 59,95% 55,28% Total 68 192 808 100,00% 100,00% 70 469 595 100,00% 100,00% 72 746 382 100,00% 100,00% (1) All classes of shares are affected. The number of ordinary shares amounts to 61,430,129 before the Private Placement, 63,706,916 after the Private Placement (but before exercise of the BSAs), and 65,983,703 after the Private Placement and exercise of the BSAs.(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).(3) AMY SAS is a company controlled by A. Moussy. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.97% on a non-diluted basis and 0.77% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on August 7, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 24, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. August 1st, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). August 4, 2025 Publication of this press of the Information Document. August 7, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. August 7, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. August 11, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - August 2025 Press Release US VFSign in to access your portfolio